About the Company
Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia. For additional information, please visit our website at http://www.memorypharma.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that are subject to
risks and uncertainties. All statements, other than statements of historical
facts, regarding management's expectations, beliefs, goals, plans or Memory
Pharmaceuticals' prospects, future financial position, future revenues and
projected costs should be considered forward-looking. Readers are cautioned
that actual results may differ materially from projections or estimates due to
a variety of important factors, including the outcome of clinical trials of
Memory Pharmaceuticals' drug candidates and whether they demonstrate these
candidates' safety and effectiveness; the risks and uncertainties associated
with: the possibility that the Company's acquisition by Roche will not be
completed, obtaining additional financing to support Memory Pharmaceuticals'
R&D and clinical activities and operations; obtaining regulatory approvals to
conduct clinical trials and to commercialize Memory Pharmaceuticals' drug
candidates; Memory Pharmaceuticals' ability to enter into and maintain
collaborations with third parties for its drug development programs; Memory
Pharmaceuticals' dependence on its collaborations and its license
relationships; achieving milestones under Memory Pharmaceuticals'
col
'/>"/>
| SOURCE Memory Pharmaceuticals Corp. Copyright©2008 PR Newswire. All rights reserved |